SG11202008029UA - 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof - Google Patents
5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereofInfo
- Publication number
- SG11202008029UA SG11202008029UA SG11202008029UA SG11202008029UA SG11202008029UA SG 11202008029U A SG11202008029U A SG 11202008029UA SG 11202008029U A SG11202008029U A SG 11202008029UA SG 11202008029U A SG11202008029U A SG 11202008029UA SG 11202008029U A SG11202008029U A SG 11202008029UA
- Authority
- SG
- Singapore
- Prior art keywords
- carboxamides
- preparation
- heteroaryl substituted
- substituted indazole
- indazole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862634656P | 2018-02-23 | 2018-02-23 | |
PCT/US2019/019129 WO2019165192A1 (en) | 2018-02-23 | 2019-02-22 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202008029UA true SG11202008029UA (en) | 2020-09-29 |
Family
ID=65812386
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202008029UA SG11202008029UA (en) | 2018-02-23 | 2019-02-22 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof |
Country Status (18)
Country | Link |
---|---|
US (2) | US10934297B2 (en) |
EP (1) | EP3755696B1 (en) |
JP (1) | JP7369132B2 (en) |
KR (1) | KR20200126393A (en) |
CN (1) | CN112020501A (en) |
AU (1) | AU2019224075A1 (en) |
BR (1) | BR112020017087A2 (en) |
CA (1) | CA3091913A1 (en) |
CL (1) | CL2020002177A1 (en) |
EA (1) | EA202092002A1 (en) |
ES (1) | ES2945558T3 (en) |
IL (1) | IL276814A (en) |
MA (1) | MA51908A (en) |
MX (1) | MX2020008852A (en) |
PE (1) | PE20211447A1 (en) |
PH (1) | PH12020551300A1 (en) |
SG (1) | SG11202008029UA (en) |
WO (1) | WO2019165192A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2945558T3 (en) | 2018-02-23 | 2023-07-04 | Biosplice Therapeutics Inc | 5-heteroaryl substituted indazol-3-carboxamides and preparation and use thereof |
HRP20220664T1 (en) * | 2018-05-07 | 2022-06-24 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
WO2020059841A1 (en) * | 2018-09-21 | 2020-03-26 | 国立大学法人 長崎大学 | Therapeutic agent for prion diseases |
BR112022011639A2 (en) * | 2019-12-16 | 2022-08-30 | Korea Res Inst Chemical Tech | INDAZOLE DERIVATIVES AND USE THEREOF |
WO2021120890A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Pyrazolyl derivatives useful as anti-cancer agents |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4164559A (en) | 1977-09-21 | 1979-08-14 | Cornell Research Foundation, Inc. | Collagen drug delivery device |
US4474752A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
US6440102B1 (en) | 1998-07-23 | 2002-08-27 | Durect Corporation | Fluid transfer and diagnostic system for treating the inner ear |
DE19853299C2 (en) | 1998-11-19 | 2003-04-03 | Thomas Lenarz | Catheter for the application of medication in fluid spaces of the human inner ear |
US6120484A (en) | 1999-02-17 | 2000-09-19 | Silverstein; Herbert | Otological implant for delivery of medicament and method of using same |
US6967023B1 (en) | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
YU54202A (en) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Indazole compounds,pharmaceutical compositions,and methods for mediating or inhibiting cell proliferation |
US6648873B2 (en) | 2001-09-21 | 2003-11-18 | Durect Corp. | Aural catheter system including anchor balloon and balloon inflation device |
GB0218625D0 (en) * | 2002-08-10 | 2002-09-18 | Astex Technology Ltd | Pharmaceutical compounds |
KR101129933B1 (en) | 2002-09-25 | 2012-03-23 | 메모리 파마슈티칼스 코포레이션 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
FR2845382A1 (en) | 2002-10-02 | 2004-04-09 | Sanofi Synthelabo | INDAZOLECARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS |
US7008953B2 (en) | 2003-07-30 | 2006-03-07 | Agouron Pharmaceuticals, Inc. | 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
FR2867778B1 (en) * | 2004-03-16 | 2006-06-09 | Sanofi Synthelabo | USE OF INDAZOLECARBOXAMIDE DERIVATIVES FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT AND PREVENTION OF MALARIA |
US20050234095A1 (en) | 2004-03-25 | 2005-10-20 | Wenge Xie | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof |
UA93348C2 (en) * | 2004-03-25 | 2011-02-10 | Меморі Фармас'Ютікалз Корпорейшн | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, preparation and uses thereof |
WO2011050245A1 (en) * | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
JP5855253B2 (en) * | 2011-08-12 | 2016-02-09 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Indazole compounds, compositions and methods of use |
KR102010611B1 (en) | 2011-09-14 | 2019-08-13 | 사뮤메드, 엘엘씨 | Indazole-3-carboxamides and their use as WNT/β-catenin signaling pathway inhibitors |
SG10201701649YA (en) * | 2012-02-21 | 2017-04-27 | Acraf | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
CA2942687A1 (en) | 2014-03-20 | 2015-09-24 | Samumed, Llc | 5-substituted indazole-3-carboxamides and preparation and use thereof |
WO2016040182A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof |
WO2017079759A1 (en) | 2015-11-06 | 2017-05-11 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-c]pyridines and their anti-inflammatory uses thereof |
SG10201912248RA (en) | 2016-06-01 | 2020-02-27 | Samumed Llc | Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide |
MX2019004616A (en) | 2016-10-21 | 2019-11-21 | Samumed Llc | Methods of using indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors. |
ES2945558T3 (en) | 2018-02-23 | 2023-07-04 | Biosplice Therapeutics Inc | 5-heteroaryl substituted indazol-3-carboxamides and preparation and use thereof |
-
2019
- 2019-02-22 ES ES19711736T patent/ES2945558T3/en active Active
- 2019-02-22 EP EP19711736.9A patent/EP3755696B1/en active Active
- 2019-02-22 MX MX2020008852A patent/MX2020008852A/en unknown
- 2019-02-22 CN CN201980027314.1A patent/CN112020501A/en active Pending
- 2019-02-22 CA CA3091913A patent/CA3091913A1/en active Pending
- 2019-02-22 KR KR1020207027174A patent/KR20200126393A/en not_active Application Discontinuation
- 2019-02-22 JP JP2020544501A patent/JP7369132B2/en active Active
- 2019-02-22 MA MA051908A patent/MA51908A/en unknown
- 2019-02-22 EA EA202092002A patent/EA202092002A1/en unknown
- 2019-02-22 SG SG11202008029UA patent/SG11202008029UA/en unknown
- 2019-02-22 WO PCT/US2019/019129 patent/WO2019165192A1/en unknown
- 2019-02-22 AU AU2019224075A patent/AU2019224075A1/en not_active Abandoned
- 2019-02-22 US US16/283,366 patent/US10934297B2/en active Active
- 2019-02-22 PE PE2020001271A patent/PE20211447A1/en unknown
- 2019-02-22 BR BR112020017087-9A patent/BR112020017087A2/en not_active IP Right Cessation
-
2020
- 2020-08-19 IL IL276814A patent/IL276814A/en unknown
- 2020-08-20 PH PH12020551300A patent/PH12020551300A1/en unknown
- 2020-08-24 CL CL2020002177A patent/CL2020002177A1/en unknown
- 2020-12-30 US US17/138,098 patent/US11713320B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
IL276814A (en) | 2020-10-29 |
JP2021516674A (en) | 2021-07-08 |
ES2945558T3 (en) | 2023-07-04 |
US10934297B2 (en) | 2021-03-02 |
BR112020017087A2 (en) | 2020-12-22 |
US20190263821A1 (en) | 2019-08-29 |
EA202092002A1 (en) | 2021-01-21 |
AU2019224075A1 (en) | 2020-09-10 |
EP3755696A1 (en) | 2020-12-30 |
US20220402921A1 (en) | 2022-12-22 |
WO2019165192A1 (en) | 2019-08-29 |
JP7369132B2 (en) | 2023-10-25 |
PE20211447A1 (en) | 2021-08-05 |
CL2020002177A1 (en) | 2021-01-08 |
MA51908A (en) | 2021-06-02 |
PH12020551300A1 (en) | 2021-10-25 |
CN112020501A (en) | 2020-12-01 |
MX2020008852A (en) | 2020-10-14 |
US11713320B2 (en) | 2023-08-01 |
EP3755696B1 (en) | 2023-04-05 |
CA3091913A1 (en) | 2019-08-29 |
KR20200126393A (en) | 2020-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202001447B (en) | M-diamide compound and preparation method therefor and use thereof | |
IL274710A (en) | Indole compounds and their use | |
IL276814A (en) | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | |
GB201715194D0 (en) | Compounds and their therapeutic use | |
IL277749A (en) | Pladienolide compounds and their use | |
IL284514A (en) | Halo-allylamine compounds and use thereof | |
IL277502A (en) | Compounds and uses thereof | |
IL269836B (en) | Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof | |
IL280644A (en) | Magnesium-serinate compound and use thereof | |
IL276323A (en) | 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof | |
IL282527A (en) | Azaindazole-5 derivatives and their use | |
PT3796975T (en) | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | |
SG11202008543RA (en) | Pyrrolidineamide derivatives and uses thereof | |
IL264403A (en) | Vortioxetine analogue and use and preparation thereof | |
IL279483A (en) | Cyanotriazole compounds and uses thereof | |
IL282526A (en) | Azaindazole-5 derivatives and their use | |
IL276984A (en) | Insecticidal composition and use thereof | |
GB201813312D0 (en) | Compounds and their therapeutic use | |
IL282142A (en) | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | |
IL280369A (en) | New myokines and uses thereof | |
IL269843B (en) | Substituted n-arylethyl-2-arylquinoline-4-carboxamides and use thereof | |
GB201906914D0 (en) | Substituted naphtahlene diimdes and their use | |
GB2562083B (en) | Fungicidal composition and use thereof | |
IL283540A (en) | Dock1-inhibiting compound and use thereof | |
GB201813311D0 (en) | Novel compounds and their use |